Table 1.
Clinicopathological data of the 460 breast cancer patients used in the study
| Characteristic | Mean (range) | N = 460 | % |
|---|---|---|---|
| Follow-up (years) | 11.8 (0.16-27.55) | ||
| Age (years) | 58.3 (23–89) | ||
| <45 | 90 | 20 | |
| 45-55 | 106 | 23 | |
| 55-65 | 107 | 23 | |
| ≥65 | 157 | 34 | |
| Tumor size (T) | |||
| 1 | 182 | 40 | |
| 2 | 227 | 49 | |
| 3-4 | 51 | 11 | |
| Nodal status (N) | |||
| Negative | 236 | 51 | |
| Positive | 224 | 49 | |
| ER | |||
| Positive | 204 | 44 | |
| Negative | 256 | 56 | |
| PgR | |||
| Positive | 223 | 49 | |
| Negative | 237 | 51 | |
| HER2 | |||
| No overexpression | 413 | 90 | |
| Overexpression | 47 | 10 | |
| Histologic type | |||
| Ductal | 418 | 91 | |
| Other | 42 | 9 | |
| Tumor grade | |||
| 1 | 71 | 16 | |
| 2 | 222 | 48 | |
| 3 | 167 | 36 | |
| Local treatment | |||
| Mastectomy without RT | 180 | 39 | |
| Mastectomy with RT | 97 | 21 | |
| BCS with RT | 183 | 40 | |
| Systemic treatment | |||
| Chemotherapy alone | 89 | 19 | |
| Endocrine therapy alone | 77 | 17 | |
| Chemo- and endocrine therapy | 18 | 4 | |
| None | 276 | 60 |
Clinicopathological characteristics of the cohort of breast cancer patients. Statistical analyses were performed with all patients (n = 460) with complete clinicopathological data and nuclear staining data for LSD1, HDAC2 and SIRT1. Tumor size (T) and nodal status (N) were based on the TNM staging criteria. ER: estrogen receptor, PgR: progesterone receptor, HER2: human epidermal growth factor receptor 2, RT: radiotherapy, BCS: breast conserving surgery.